Cellebrite DI Exceeds Q1 2026 Earnings Guidance Driven by AI Adoption - HarianBasis.co

Cellebrite DI Exceeds Q1 2026 Earnings Guidance Driven by AI Adoption Michael Anderson Published May 16, 2026 - 04:35 Share WhatsApp Smallest Font Largest Font Table of Contents [ Show ] Cellebrite DI Ltd. delivered first-quarter 2026 financial results that reached or surpassed the upper limits of its previous forecasts. As reported by Detik Finance, the digital intelligence firm saw its annual recurring revenue (ARR) climb 21% to reach $493 million. The company also reported a 19% increase in total revenue, amounting to $128.3 million for the period. Adjusted EBITDA experienced a significant jump of 29%, settling at $30.6 million, while the company maintained a high gross margin of 86%. Chief Executive Officer Tom Hogan highlighted that the company's trailing 12-month free cash flow margin stood at 32%. Hogan also noted that Cellebrite’s "rule of x" metric continues to track consistently above the 50 mark. The latest earnings call emphasized a major shift toward AI-integrated products. Management specifically pointed to the launch of Genesis, an agentic next-generation AI solution designed to extract insights from complex digital evidence. Since its announcement on March 16, Genesis has already attracted more than 500 registered users across 15 different countries. The platform is currently available to early adopters before its scheduled general availability in mid-June. Cellebrite has also moved its Guardian Investigate platform to general availability. Executives noted that the company is continuing to expand its capabilities in mobile device unlocking to support law enforcement and investigative agencies. Financial Performance and Subscription Growth Chief Financial Officer David Barter reported that subscription revenue grew by 23% during the quarter. This growth helped offset a planned reduction in non-recurring revenue streams such as hardware, professional services, and training. Adjusted EBITDA margins expanded by 190 basis points to reach 23.9%. This expansion occurred despite the impact of foreign exchange fluctuations and the inclusion of full-quarter operating costs from the Corellium acquisition. The company ended the first quarter with $535 million in cash, cash equivalents, and investments. This balance remained stable compared to the end of 2025, primarily due to capital used for the acquisition of SCG Canada. Outlook for the US Federal Market Management expressed optimism regarding a rebound in the U.S. federal business sector. This recovery is supported by the achievement of FedRAMP High authorization and a 35% year-over-year growth in the federal sales pipeline. Looking ahead, Cellebrite reaffirmed its full-year guidance for 2026. For the second quarter, the company expects ARR to fall between $510 million and $513 million, representing a projected revenue growth of 15% to 17%. Cellebrite DI Q1 2026 Financial Highlights Metric Q1 2026 Value Year-over-Year Growth Annual Recurring Revenue $493 million 21% Total Revenue $128.3 million 19% Adjusted EBITDA $30.6 million 29% Gross Margin 86% N/A "Genesis is designed to deliver rapid insights from complex and disparate digital evidence sources," Hogan stated when describing the company's newest AI-driven agentic solution. Advertisement Scroll To Continue with Content Finance Tech Stocks Artificial Intelligence Editors Team What's Your Reaction? 0 0 0 0 0 0